Immunization

Bystander Effect Seen After Vector Administration

Published in Vaccine Weekly, October 10th, 2001

by Sonia Nichols, senior medical writer - Gene therapies containing herpes simplex enzymes might be useful for immunizing patients against the formation of new tumors, according to scientists working in the U.S.

A team led by researchers at the National Human Genome Research Institute of Bethesda, Maryland, has reported gene therapy vectors expressing herpes simplex thymidine kinase (HSVtk) tend to boost some parts of the immune system, essentially preventing the formation of new tumors as well as killing existing tumors.

"We have observed the development of cytotoxic T lymphocyte (CTL) populations and long-lasting antitumor immunity following...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry